Arrowhead Pharmaceuticals (ARWR) Net Cash Flow (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Net Cash Flow data on file, last reported at -$14.1 million in Q1 2026.

• Quarterly Net Cash Flow fell 110.68% year-over-year to -$14.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 96.99% YoY) and the FY2025 annual result came in at $124.3 million, up 1101.89% from the prior year.
• Net Cash Flow rose to -$14.1 million in Q1 2026, from -$25.0 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $132.2 million in Q1 2025 to a low of -$67.2 million in Q1 2023.
• A 5-year average of $5.4 million and a median of -$14.1 million in 2026 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 1197.61% — and 2024, when it surged 435.71%.
• Tracing ARWR's Net Cash Flow over 5 years: stood at $94.4 million in 2022, then slumped by 155.88% to -$52.7 million in 2023, then grew by 7.6% to -$48.7 million in 2024, then soared by 48.67% to -$25.0 million in 2025, then jumped by 43.53% to -$14.1 million in 2026.
• The last three Net Cash Flow figures came in at -$14.1 million (Q1 2026), -$25.0 million (Q4 2025), and $96.8 million (Q3 2025), per Business Quant data.